1stOncology™: Cancer Intelligence Service – Page 10775 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Ionis to hold third quarter 2020 financial results webcast

On October 21, 2020 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) reported that it will host a live webcast on Wednesday, November 4th at 11:30 a.m. Eastern Time to discuss its third quarter 2020 financial results and report on pipeline and business progress (Press release, Ionis Pharmaceuticals, OCT 21, 2020, View Source [SID1234568765]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Interested parties may access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address.

CytoSorbents to Report Q3 2020 Operating and Financial Results

On October 21, 2020 CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reported that it will report Q3 2020 financial results after the market close on Wednesday, November 4, 2020 (Press release, Cytosorbents, OCT 21, 2020, View Source [SID1234568764]). CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q3 2020 followed by a question and answer session.

Conference Call Details:
Date: Wednesday, November 4, 2020
Time: 4:45 PM Eastern
Participant Dial-In: 877-451-6152
Conference ID: 13711756
Live Presentation Webcast: View Source

It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: View Source

An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at View Source

CryoLife Announces Release Date and Teleconference Call Details for 2020 Third Quarter Financial Results

On October 21, 2020 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, reported that 2020 third quarter financial results will be released on Wednesday, November 4, 2020 after the market closes (Press release, CryoLife, OCT 21, 2020, View Source [SID1234568762]). On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. A replay of the teleconference will be available November 4 through November 11, 2020 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13712302.

The live webcast and replay can be accessed in the Investor Relations section of the CryoLife website at www.cryolife.com and selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investor Relations section of the CryoLife website.

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

On October 21, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, reported that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submission of a Pre-IND Meeting request to the FDA on its anti-tumor Drug Candidate CANNABICS RCC-33, the world’s first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer (Press release, Cannabics Pharmaceuticals, OCT 21, 2020, View Source [SID1234568761]). The pre-IND Meeting request with the FDA is expected to be submitted during Q1 of 2021, and subsequently take place in the first half of 2021.

Eyal Barad, Cannabics Pharmaceuticals CEO, said: "The company’s decision to move forward with an FDA regulatory path for this specific product is based on a combination of factors including: the promising pre-clinical findings from our licensed in-house Drug Discovery platform in Israel, our proprietary related IP, and our positive market analysis. After many years of R&D and of developing our expertise in anti-cancer drug discovery, we are truly excited to have developed what we believe to be the world’s first cannabinoid-based medicine targeting colorectal cancer."

Prior to filing the request for a pre-IND Meeting, the company plans to carry out a Proof of Concept (POC) study using In-vivo animal models, and a completion of the synopsis of the first in-human phase 1/2a clinical study. All this in conjunction with the development of the CANNABICS RCC-33’s clinical Chemistry Manufacturing & Control (CMC) protocols.

Dr. Eyal Ballan, Cannabics Pharmaceuticals CTO, said "This cooperation has enabled the company to factor in cumulative experience for approaching the FDA on a cannabinoid-based drugs for various specific indications, and we are confident that this collective experience will prove invaluable in the clinical validation process for our CANNABICS RCC-33."

Nordic Nanovector ASA: Cancellation of Repair Offering

On October 21, 2020 Reference is made to the stock exchange announcement by Nordic Nanovector ASA (the "Company") on 23 and 30 September 2020 where the Company reported the successful completion of a private placement raising gross proceeds of approximately NOK 231 million (the "Private Placement") and that the board of directors would consider to carry out a repair offering of up to 2,285,714 new shares in the Company (the "Repair Offering") (Press release, Nordic Nanovector, OCT 21, 2020, View Source [SID1234568760]).

The Company has decided not to proceed with the Repair Offering. Since the announcement of completion of the Private Placement, the Company’s shares have traded on the Oslo Stock Exchange, with significant trading volume, at prices close to or below the subscription price in the Private Placement of NOK 17.50. Accordingly, any shareholders wishing to neutralize the dilutive effect of the Private Placement have had the opportunity to purchase shares in the Company in the market, at prices close to or below what would have been the subscription price in a Repair Offering. In light of this, the Company has resolved not to proceed with a Repair Offering that would have resulted in additional costs for the Company.